<?xml version="1.0" encoding="UTF-8"?>
<p id="Par6">Today, we can accelerate these activities and enable production capacity for clinical studies for therapeutic mAbs. What could be the fastest path to provide mAbs for clinical evaluation during a pandemic outbreak? I propose that the answer could be 5–6 months, rather than 10–12 months.</p>
